Last updated: 2026-09-09 17:37:40. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Alzamend Neuro, Inc. (ALZN) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1,68, with a market capitalisation of $8,01M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0,84 to $2,68. This page covers its latest market performance, valuation, price trends and company information.
$8,01M | |
$1,68 | |
$45.292,50 | |
$0,84 | |
$1,68 | |
4,95K | |
159,39K | |
-- | |
$2,68 | |
$0,84 | |
-- | |
-- |
Alzamend Neuro, Inc. (ALZN) is currently trading at $1,68 as of 2026-09-09 17:27:00, unchanged from the previous close of $1,68
During today's regular trading session, ALZN has traded between $0,84 and $45.292,50, with a trading volume of 4,95K shares. The current price is near the lower end of today's range.
Over the past seven days, Alzamend Neuro, Inc. (ALZN) moved from $1,66 to $1,68, representing a gain of 1,20% ($0,02).
The stock traded between $1,51 and $1,73 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 89,56 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 45,7%
ALZN is currently trading at $1,68, placing it 45,7% of the way from its 52-week low of $0,84 to its 52-week high of $2,68. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's disease. The Company has two therapeutic drug candidates, AL001 and ALZN002. Its pipeline consists of AL001, a patented ionic cocrystal technology delivering lithium through a therapeutic combination of lithium, proline and salicylate; and ALZN002, a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's disease.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 6 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Alzamend Neuro, Inc. (ALZN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.